Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND Inflammation biomarkers have been introduced into clinical practice for risk-rating in treatment of patients with cancer. We aimed to confirm the prognostic role of platelet-to-lymphocyte ratio (PLR) as a powerful biomarker for patients with advanced cancer. METHOD A systematic literature search was conducted through PubMed, Embase and Web of Science databases for studies on advanced tumors. Research articles that analyzed the PLR and hazard ratios (HR) in patients with overall survival (OS) or progression-free survival (PFS) data were involved. Two authors assessed the eligibility of trials and extracted data independently. Meta-analyses were performed with random-effect models. Data heterogeneity was calculated with the I2 method. RESULTS Thirty-three eligible cohort studies including 8215 patients were further analyzed. Elevated PLR was associated with reduced OS (HR = 1.45, 95% CI, 1.31-1.61, p < 0.001) and PFS (HR = 1.73, 95% CI, 1.31-2.29, p < 0.001) in patients with advanced cancer. A extreme result was observed in a subgroup analysis in metastatic renal cancer with the worst OS (HR = 2.47, 95% CI, 1.32-4.62, p = .005) and PFS (HR = 3.89, 95% CI, 1.23-12.28, p = 0.021). CONCLUSIONS Patients with high pretreatment blood PLR level have poor OS and PFS. Further investigations are needed to explore the underlying mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Inflammation and Cancer: Is the Link as Simple as We Think?
Nickoloff, B. J., Ben-Neriah, Y., & Pikarsky, E. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23724.x · Cited by 110
The Prognostic Value of Platelet-to-Lymphocyte Ratio in Urological Cancers: A Meta-Analysis
Li, D.-Y., Hao, X.-Y., Ma, T.-M., Dai, H.-X., & Song, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15673-2 · Cited by 44
Cited by
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Dionisie, V., Filip, G. A., Manea, M. C., Movileanu, R. C., Moisa, E., Manea, M., Riga, S., & Ciobanu, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091924 · Cited by 82
Kulacaoglu, F., Yıldırım, Y. E., Aslan, M., & İzci, F. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2116106 · Cited by 18
Pęksa, R., Kunc, M., Popęda, M., Piątek, M., Bieńkowski, M., Żok, J., Starzyńska, A., Perdyan, A., Sowa, M., Duchnowska, R., et al. (2021) · Cancers · doi:10.3390/cancers13081750 · Cited by 16
“Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-tomonocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) are considered a simple measure of systemic inflammatory response and carry potentially prognostic information in various cancers [6,23,24].”
Background
Metadata
- Authors
- Li, B., Zhou, P., Liu, Y., Wei, H., Yang, X., Chen, T., & Xiao, J.
- Venue
- Clinica Chimica Acta
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 483
- Pages
- 48-56
- ISSN
- 0009-8981 (ISSN-L)
- OpenAlex
- W2801803191
- Cited by
- 230
- References
- 7
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.